ALF 5755

Drug Profile

ALF 5755

Alternative Names: ALF-5755; Recombinant hepatocarcinoma-intestine-pancreas pancreatitis-associated protein; Recombinant HIP/PAP; rhHIP/PAP

Latest Information Update: 09 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM
  • Developer Alfact Innovation
  • Class Growth factors; Lectins; Neuroprotectants; Recombinant proteins
  • Mechanism of Action Antioxidants; Growth stimulants; Pancreatitis-associated protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alcoholic hepatitis; Hepatitis; Liver cirrhosis; Liver disorders; Liver failure; Neurological disorders

Most Recent Events

  • 09 Feb 2016 No development reported - Phase-I for Alcoholic hepatitis (In volunteers) in France (IV)
  • 09 Feb 2016 No development reported - Phase-I for Cirrhosis (In volunteers) in France (IV)
  • 09 Feb 2016 No development reported - Phase-I for Liver disorders (Prevention, In volunteers) in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top